rewirebio.iobenchmarks
Configuration

Alternative post-hoc detection criterion (Sanderson et al. 2026)

The nanopore CMg workflow with the alternative post-hoc detection criterion.

1 evaluation · 6 results

Overview

An explanatory profile has not yet been reviewed for this record.

Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.

Evaluations and results

1 evaluation · 6 results. Different protocols are not a single leaderboard.

Protocol: Target-level detection of respiratory pathogens against routine multiplex PCR, validation set (Sanderson et al. 2026) · Dataset: Validation set: 344 prospectively collected nasopharyngeal swabs (Sanderson et al. 2026)

Sorted by Recall (all PCR targets; target level; reference: routine multiplex PCR) (higher is better). The best value in each column is highlighted. Decimals are rounded for display; each value links to the printed value and its source.

Tested configurationRecall (all PCR targets; target level; reference: routine multiplex PCR)Recall (RNA pathogen targets excluding rhinovirus and enterovirus; target level; reference: routine multiplex PCR)Recall (RNA pathogen targets only (adenovirus and bacteria excluded); target level; reference: routine multiplex PCR)Recall (targets detectable by study qPCR; target level; reference: routine multiplex PCR)Recall (targets with study qPCR Ct < 35; target level; reference: routine multiplex PCR)Specificity (all PCR targets; target level; reference: routine multiplex PCR)
Alternative post-hoc detection criterion (Sanderson et al. 2026)Evaluation58%70%61%75%83%99.9%
All 6 result rows with coverage, uncertainty and sources
Filter evaluations

Applied filters: All linked evaluations

Exact evaluated configurations and original reported results
Tested configurationProtocol and datasetFindingEvidence and details
Configuration: Alternative post-hoc detection criterion (Sanderson et al. 2026)Protocol: Target-level detection of respiratory pathogens against routine multiplex PCR, validation set (Sanderson et al. 2026)
Dataset: Validation set: 344 prospectively collected nasopharyngeal swabs (Sanderson et al. 2026)
58% Recall (all PCR targets; target level; reference: routine multiplex PCR)
percent · higher

Uncertainty: 95% CI 52 to 64

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Alternative post-hoc detection criterion on the validation set (Sanderson et al. 2026)

rna-pathogen-20261011-sanderson2026-protocol-validation

Aggregation: Not reported

Clinical validation of a novel metagenomic nanopore sequencing method for detecting viral respiratory pathogens: diagnostic accuracy study · Results 'Validation Set: Diagnostic performance' paragraph 6: "increased sensitivity to 58% (95% CI 52-64%; 159/274)"
Configuration: Alternative post-hoc detection criterion (Sanderson et al. 2026)Protocol: Target-level detection of respiratory pathogens against routine multiplex PCR, validation set (Sanderson et al. 2026)
Dataset: Validation set: 344 prospectively collected nasopharyngeal swabs (Sanderson et al. 2026)
83% Recall (targets with study qPCR Ct < 35; target level; reference: routine multiplex PCR)
percent · higher

Uncertainty: 95% CI 76 to 88

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Alternative post-hoc detection criterion on the validation set (Sanderson et al. 2026)

rna-pathogen-20261011-sanderson2026-protocol-validation

Aggregation: Not reported

Clinical validation of a novel metagenomic nanopore sequencing method for detecting viral respiratory pathogens: diagnostic accuracy study · Results 'Performance by viral load (Cn,Ct)' paragraph 2: "increased further to 83% (95% CI, 76-88%) when restricting to qPCR Ct <35"
Configuration: Alternative post-hoc detection criterion (Sanderson et al. 2026)Protocol: Target-level detection of respiratory pathogens against routine multiplex PCR, validation set (Sanderson et al. 2026)
Dataset: Validation set: 344 prospectively collected nasopharyngeal swabs (Sanderson et al. 2026)
75% Recall (targets detectable by study qPCR; target level; reference: routine multiplex PCR)
percent · higher

Uncertainty: 95% CI 68 to 81

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Alternative post-hoc detection criterion on the validation set (Sanderson et al. 2026)

rna-pathogen-20261011-sanderson2026-protocol-validation

Aggregation: Not reported

Clinical validation of a novel metagenomic nanopore sequencing method for detecting viral respiratory pathogens: diagnostic accuracy study · Results 'Performance by viral load (Cn,Ct)' paragraph 2: "sensitivity increased to 75% (95% CI, 68-81%)"
Configuration: Alternative post-hoc detection criterion (Sanderson et al. 2026)Protocol: Target-level detection of respiratory pathogens against routine multiplex PCR, validation set (Sanderson et al. 2026)
Dataset: Validation set: 344 prospectively collected nasopharyngeal swabs (Sanderson et al. 2026)
70% Recall (RNA pathogen targets excluding rhinovirus and enterovirus; target level; reference: routine multiplex PCR)
percent · higher

Uncertainty: 95% CI 63 to 76

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Alternative post-hoc detection criterion on the validation set (Sanderson et al. 2026)

rna-pathogen-20261011-sanderson2026-protocol-validation

Aggregation: Not reported

Clinical validation of a novel metagenomic nanopore sequencing method for detecting viral respiratory pathogens: diagnostic accuracy study · Results 'Performance by pathogen' paragraph 2 (after Figure 6 and its legend): "increased overall sensitivity using the alternative criteria further to 70% (145/207) (95% CI 63%-76%)"
Configuration: Alternative post-hoc detection criterion (Sanderson et al. 2026)Protocol: Target-level detection of respiratory pathogens against routine multiplex PCR, validation set (Sanderson et al. 2026)
Dataset: Validation set: 344 prospectively collected nasopharyngeal swabs (Sanderson et al. 2026)
61% Recall (RNA pathogen targets only (adenovirus and bacteria excluded); target level; reference: routine multiplex PCR)
percent · higher

Uncertainty: 95% CI 55 to 67

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Alternative post-hoc detection criterion on the validation set (Sanderson et al. 2026)

rna-pathogen-20261011-sanderson2026-protocol-validation

Aggregation: Not reported

Clinical validation of a novel metagenomic nanopore sequencing method for detecting viral respiratory pathogens: diagnostic accuracy study · Results 'Performance by pathogen' paragraph 2 (after Figure 6 and its legend): "increased sensitivity using the alternative criteria to 61% (159/260) (95% CI 55-67%)"
Configuration: Alternative post-hoc detection criterion (Sanderson et al. 2026)Protocol: Target-level detection of respiratory pathogens against routine multiplex PCR, validation set (Sanderson et al. 2026)
Dataset: Validation set: 344 prospectively collected nasopharyngeal swabs (Sanderson et al. 2026)
99.9% Specificity (all PCR targets; target level; reference: routine multiplex PCR)
percent · higher

Uncertainty: 95% CI 99.8 to 100

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Alternative post-hoc detection criterion on the validation set (Sanderson et al. 2026)

rna-pathogen-20261011-sanderson2026-protocol-validation

Aggregation: Not reported

Clinical validation of a novel metagenomic nanopore sequencing method for detecting viral respiratory pathogens: diagnostic accuracy study · Results 'Validation Set: Diagnostic performance' paragraph 6: "improved specificity to 99.9% (95% CI 99.8-100%; 4015/4017)"

Source checking is not independent reproduction. Release 2026-10-22-1b7cf027e4f6.

Use this configuration

How it works, versions and access
Strengths, limitations and unresolved questions

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

0 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-10-22-1b7cf027e4f6
Property and statementOriginal source and locationReview and provenance

No evidence rows match these filters. Choose another scope or clear the search.

Sources and history

Release 2026-10-22-1b7cf027e4f6 · Record review: source checked

1 source record and release historyDownload this release (gzip)
Technical metadata and extraction receipts

Stable ID: rna-pathogen-20261011-sanderson2026-config-alternative

areas
microbes-communities
contexts
clinical_research
method types
conventional_pipeline
reported name
Alternative post-hoc detection criterion
parameters
Reads mapping to the target genome as a percentage of reads on the run mapping to that genome > 0.037%, AND >= 2 target reads, replacing the main and ratio criteria; chosen after the validation results
source locator
Results 'Validation Set: Diagnostic performance' paragraph 6
foundation model eligible
false
access reuse
Laboratory workflow described in the preprint; not a released product
missing metadata
version: reason: unreported; note: minimap2 and basecaller versions are not given in the inspected text
Related records

Suggest a correction